Type 2 Diabetes - newer agents (partial update of CG66)
Type 2 Diabetes - newer agents (partial update of CG66)
Summary
The advice in the NICE guideline covers: the monitoring of glucose, lipid (blood cholesterol and fat) and blood pressure levels diabetes education programmes dietary advice the use of medications to:- control blood glucose - prevent vascular (blood vessel) disease - reduce blood pressure - ...
May 2009
NICE clinical guideline 87 partially updates NICE clinical guideline 66 and replaces it. Most of the recommendations were developed for NICE clinical guideline 66 by the National Collaborating Centre for Chronic Conditions. Details of the methods and evidence used to develop these recommendations are in CG66 Type 2 diabetes: full guideline. The recommendations on DPP-4 inhibitors (sitagliptin, vildagliptin), thiazolidinediones (pioglitazone, rosiglitazone), exenatide and insulin were developed by the Centre for Clinical Practice at NICE following the process for short clinical guidelines. Details of the methods and evidence used to develop these recommendations are in CG87 Type 2 diabetes - newer agents: short guideline.
Guidance documents
Implementing this guidance
Other information
Expected review date: May 2012
About this guidance
Clinical guidelines CG87
Issued: May 2009
How this guidance was produced